Open AccessInitial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Author(s) -
Michaela A. Dinan,
Xiaojuan Mi,
Shelby D. Reed,
Bradford R. Hirsch,
Gary H. Lyman,
Lesley H. Curtis
Publication year - 2015
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2015.43
Subject(s) - medicine , breast cancer , medicaid , cancer , population , epidemiology , disease , retrospective cohort study , observational study , oncology , gynecology , health care , environmental health , economics , economic growth
In 2006, the Centers for Medicare & Medicaid Services approved coverage for the use of the 21-gene recurrence score (RS) assay in women with early-stage, estrogen receptor-positive, node-negative breast cancers to help guide recommendations for adjuvant chemotherapy. Use of the assay in community settings has not been previously examined in a nationally representative sample of patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom